The latest Lifespan.io crowdfunding project launched last month and is already closing in on the final stretch goal of $75,000; congratulations to everyone involved. The funds will be used to run a mouse study of nicotinamide mononucleotide (NMN) supplementation, one of a number of similar approaches that can increase NAD+ levels in older animals. This in turn improves mitochondrial function, though without addressing any of the underlying causes of mitochondrial decline with aging – it is a way to narrowly compensate for some of the metabolic consequences of aging, or to selectively override some of the reactions to the biochemical damage of aging. It isn’t repair, but it clearly produces some benefits. A study of increased NAD+ levels using the alternative approach of nicotinamide riboside supplementation in older humans showed a reduction in blood pressure, most likely by improving the performance of smooth muscle cells in blood vessel walls. The metrics taken over the course of this Lifespan.io funded mouse study will allow researchers to assess the degree to which the NMN intervention can slow aging in mice.
Yesterday, we announced the successful completion